SK Biopharmaceuticals - Public Comps and Valuation Multiples

SK Biopharmaceuticals Overview

About SK Biopharmaceuticals

SK Biopharmaceuticals Co Ltd is a pharmaceutical company engaged in the research and development of new drugs for the treatment of central nervous system (CNS) disorders. The company is also researching the development of drugs to treat brain tumors, including metastatic tumors. Its drug pipeline includes Cenobamate, Solriamfetol, Carisbamate, Relenopride, SKL13865, SKL20540, SKL-PSY, and more.

Founded

2011

HQ

Employees

265

Website

skbp.com

Sectors

Drug Development & Therapeutics
BioTech

Financials

LTM Revenue $491M

LTM EBITDA $149M

EV

$6.4B

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

SK Biopharmaceuticals Financials

As of December 2025, SK Biopharmaceuticals reported last 12-month revenue of $491M and EBITDA of $149M.

In the same period, SK Biopharmaceuticals generated $461M in LTM gross profit and $106M in net income.

See SK Biopharmaceuticals valuation multiples based on analyst estimates

SK Biopharmaceuticals P&L

In the most recent fiscal year, SK Biopharmaceuticals reported revenue of $378M and EBITDA of $69.5M.

SK Biopharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX

See SK Biopharmaceuticals valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Revenue	$491M	XXX	$378M	XXX	XXX	XXX
Gross Profit	$461M	XXX	$348M	XXX	XXX	XXX
Gross Margin	94%	XXX	92%	XXX	XXX	XXX
EBITDA	$149M	XXX	$69.5M	XXX	XXX	XXX
EBITDA Margin	30%	XXX	18%	XXX	XXX	XXX
EBIT	$144M	XXX	$66.5M	XXX	XXX	XXX
EBIT Margin	29%	XXX	18%	XXX	XXX	XXX
Net Profit	$106M	XXX	$166M	XXX	XXX	XXX
Net Margin	22%	XXX	44%	XXX	XXX	XXX
Net Debt	XXX	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for SK Biopharmaceuticals including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $491M. EBITDA for the last twelve months was $149M. In the most recent fiscal year, SK Biopharmaceuticals achieved $378M in revenue and $69.5M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2026)	Next Fiscal Year (2027)	Two Years Forward (2028)
Total Revenue	$491M	Analyst estimates available to subscribers	$378M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$461M	Analyst estimates available to subscribers	$348M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	94.1% gross margin	Analyst estimates available to subscribers	92.1% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$149M	Analyst estimates available to subscribers	$69.5M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	30.5% EBITDA margin	Analyst estimates available to subscribers	18.4% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$144M	Analyst estimates available to subscribers	$66.5M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	29.3% EBIT margin	Analyst estimates available to subscribers	17.6% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$106M	Analyst estimates available to subscribers	$166M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	21.6% net profit margin	Analyst estimates available to subscribers	44.0% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for SK Biopharmaceuticals

This financial data table provides comprehensive performance metrics for SK Biopharmaceuticals, a company based in South Korea. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

SK Biopharmaceuticals generated $491M in revenue over the last twelve months.
The company achieved $149M in EBITDA over the last twelve months.
Gross profit for the last twelve months was $461M.
Net income over the last twelve months reached $106M.

Fiscal Year Performance

In the most recent fiscal year, SK Biopharmaceuticals reported $378M in total revenue.
Fiscal year EBITDA was $69.5M.
The company maintained a gross profit margin of 92.1% in the most recent fiscal year.
EBITDA margin for the fiscal year was 18.4%.
Net profit margin reached 44.0% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for SK Biopharmaceuticals. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

SK Biopharmaceuticals Stock Performance

SK Biopharmaceuticals has current market cap of KRW 9.43T (or $6.5B), and EV of KRW 9.22T (or $6.4B).

Market Cap Evolution

SK Biopharmaceuticals Stock Data

As of January 16, 2026, SK Biopharmaceuticals's stock price is KRW 120400 (or $83).

See SK Biopharmaceuticals trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$6.4B	$6.5B	XXX	XXX	XXX	XXX	$1.42

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

SK Biopharmaceuticals Valuation Multiples

SK Biopharmaceuticals's trades at 13.0x EV/Revenue multiple, and 42.6x EV/EBITDA.

See valuation multiples for SK Biopharmaceuticals and 15K+ public comps

SK Biopharmaceuticals Financial Valuation Multiples

As of January 16, 2026, SK Biopharmaceuticals has market cap of $6.5B and EV of $6.4B.

Equity research analysts estimate SK Biopharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

SK Biopharmaceuticals has a P/E ratio of 61.5x.

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Market cap (current)	$6.5B	XXX	$6.5B	XXX	XXX	XXX
EV (current)	$6.4B	XXX	$6.4B	XXX	XXX	XXX
EV/Revenue	13.0x	XXX	13.0x	XXX	XXX	XXX
EV/EBITDA	42.6x	XXX	42.6x	XXX	XXX	XXX
EV/EBIT	44.4x	XXX	44.4x	XXX	XXX	XXX
EV/Gross Profit	13.8x	XXX	n/a	XXX	XXX	XXX
P/E	61.5x	XXX	61.5x	XXX	XXX	XXX
EV/FCF	72.4x	XXX	72.4x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get SK Biopharmaceuticals Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

SK Biopharmaceuticals Margins & Growth Rates

SK Biopharmaceuticals's last 12 month revenue growth is 28%

SK Biopharmaceuticals's revenue per employee in the last FY averaged $1.4M, while opex per employee averaged $1.1M for the same period.

SK Biopharmaceuticals's rule of 40 is 23% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

SK Biopharmaceuticals's rule of X is 102% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for SK Biopharmaceuticals and other 15K+ public comps

SK Biopharmaceuticals Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Revenue Growth	28%	XXX	24%	XXX	XXX	XXX
EBITDA Margin	30%	XXX	30%	XXX	XXX	XXX
EBITDA Growth	55%	XXX	n/a	XXX	XXX	XXX
Rule of 40	23%	XXX	59%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	102%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$1.4M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$1.1M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	9%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	29%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	75%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial